menu
    • menu
    [{"orgOrder":0,"company":"Stryker","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Bone Morphogenetic Protein-7","moa":"BMP","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Stryker","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stryker \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Stryker \/ Undisclosed"},{"orgOrder":0,"company":"Stryker","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Bone Morphogenetic Protein-7","moa":"BMP","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Stryker","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stryker \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Stryker \/ Undisclosed"},{"orgOrder":0,"company":"Stryker","sponsor":"Stryker","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Chlorhexidine","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Stryker","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Wipes","sponsorNew":"Stryker \/ Stryker","highestDevelopmentStatusID":"1","companyTruncated":"Stryker \/ Stryker"},{"orgOrder":0,"company":"Stryker","sponsor":"Stryker","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Stryker","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stryker \/ Stryker","highestDevelopmentStatusID":"10","companyTruncated":"Stryker \/ Stryker"},{"orgOrder":0,"company":"Stryker","sponsor":"Stryker","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Indocyanine Green","moa":"None","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Stryker","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Stryker \/ Stryker","highestDevelopmentStatusID":"11","companyTruncated":"Stryker \/ Stryker"},{"orgOrder":0,"company":"Stryker","sponsor":"Stryker","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Indocyanine Green","moa":"None","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Stryker","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stryker \/ Stryker","highestDevelopmentStatusID":"11","companyTruncated":"Stryker \/ Stryker"},{"orgOrder":0,"company":"Stryker","sponsor":"Stryker","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Indocyanine Green","moa":"None","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Stryker","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stryker \/ Stryker","highestDevelopmentStatusID":"6","companyTruncated":"Stryker \/ Stryker"},{"orgOrder":0,"company":"Stryker","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"IC2000","moa":"Unknown","graph1":"Oncology","graph2":"Phase III","graph3":"Stryker","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stryker \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Stryker \/ Undisclosed"},{"orgOrder":0,"company":"Stryker","sponsor":"Stryker","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Neurology","graph2":"Phase II","graph3":"Stryker","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stryker \/ Stryker","highestDevelopmentStatusID":"8","companyTruncated":"Stryker \/ Stryker"},{"orgOrder":0,"company":"Stryker","sponsor":"Stryker","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Stryker","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Stryker \/ Stryker","highestDevelopmentStatusID":"11","companyTruncated":"Stryker \/ Stryker"},{"orgOrder":0,"company":"Stryker","sponsor":"Angela Bianco","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Stryker","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stryker \/ Angela Bianco","highestDevelopmentStatusID":"8","companyTruncated":"Stryker \/ Angela Bianco"},{"orgOrder":0,"company":"Stryker","sponsor":"Kurt Weiss","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Indocyanine Green","moa":"None","graph1":"Oncology","graph2":"Phase II","graph3":"Stryker","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Stryker \/ Kurt Weiss","highestDevelopmentStatusID":"8","companyTruncated":"Stryker \/ Kurt Weiss"}]

    Find Clinical Drug Pipeline Developments & Deals by Stryker

    Menu

    Stryker

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Stryker

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Stryker

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Indocyanine Green

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase IV

                            Recipient : University of Alabama at Birmingham

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Does Fluorescence With or Without Indocyanine Green Improve Parathyroid Identification and Preservation

                            Details : Indocyanine Green is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Parathyroid Diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 13, 2023

                            Lead Product(s) : Indocyanine Green

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase IV

                            Recipient : University of Alabama at Birmingham

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Stryker

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Stryker

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Indocyanine Green

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase IV

                            Recipient : University Health Network, Toronto

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Use of Indocyanine Green to Visualize Blood Flow to the Gastrojejunostomy During Bariatric Surgery.

                            Details : Indocyanine Green is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Stomach Ulcer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 21, 2023

                            Lead Product(s) : Indocyanine Green

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase IV

                            Recipient : University Health Network, Toronto

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Stryker

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Stryker

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Indocyanine Green

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Kurt Weiss

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Fluorescent Intra-operative Tumor Margin Examination

                            Details : Indocyanine Green is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Sarcoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 22, 2021

                            Lead Product(s) : Indocyanine Green

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Kurt Weiss

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Stryker

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Stryker

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paracetamol

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Recipient : Virginia Commonwealth University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Active Temperature Management After Cardiac Surgery and Its Effect on Postoperative Cognitive Dysfunction

                            Details : Acetaminophen is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Postoperative Cognitive Complications.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 13, 2019

                            Lead Product(s) : Paracetamol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Recipient : Virginia Commonwealth University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Stryker

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Stryker

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chlorhexidine Gluconate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Angela Bianco

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Preoperative Application of Chlorhexidine to Reduce Infection With Cesarean Section After Labor

                            Details : Chlorhexidine Gluconate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Surgical Wound Infection.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 06, 2018

                            Lead Product(s) : Chlorhexidine Gluconate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Angela Bianco

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Stryker

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Stryker

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Recipient : University of Texas Health Science Center at Houston

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke

                            Details : This drug candidate is currently being evaluated in phase IV clinical studies for the treatment of Stroke.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 28, 2017

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Recipient : University of Texas Health Science Center at Houston

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Stryker

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Stryker

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IC2000

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Assessing the Safety and Effectiveness of IC2000 and SPY Fluorescence Imaging Systems (SPY-PHI) in the...

                            Details : IC2000 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 27, 2017

                            Lead Product(s) : IC2000

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Stryker

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Stryker

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chlorhexidine Gluconate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Vanderbilt University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            2% Chlorhexidine Gluconate Skin Cloths to Prevent SSI in Spine Surgery Patients

                            Details : Chlorhexidine Gluconate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Surgical Wound Infection.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 07, 2015

                            Lead Product(s) : Chlorhexidine Gluconate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Vanderbilt University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Stryker

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Stryker

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Indocyanine Green

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I

                            Recipient : Ohio State University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Near Infrared Fluorescence Cholangiography (NIRF-C) During Cholecystectomy -- Use in Acute Cholecystitis Sub-S...

                            Details : Indocyanine Green is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cholecystitis, Acute.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 25, 2014

                            Lead Product(s) : Indocyanine Green

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I

                            Recipient : Ohio State University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Stryker

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Stryker

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bone Morphogenetic Protein-7

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Double-Blind, Randomized, Single Dose Escalation Safety Study of Intraarticular Bone Morphogenic Protein (38A ...

                            Details : Bone Morphogenetic Protein-7 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Osteoarthritis, Knee.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 31, 2010

                            Lead Product(s) : Bone Morphogenetic Protein-7

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth